Last Updated: November 13, 2026

BRAVNETSA Drug Patent Profile

« Back to Dashboard


When do Bravnetsa patents expire, and what generic alternatives are available?

Bravnetsa is a drug marketed by Lantheus Medical and is included in one NDA.

The generic ingredient in BRAVNETSA is lutetium lu-177 dotatate. There is one drug master file entry for this compound. Two suppliers are listed for this compound. Additional details are available on the lutetium lu-177 dotatate profile page.

AI Deep Research
Questions you can ask:
  • What is the 5 year forecast for BRAVNETSA?
  • What are the global sales for BRAVNETSA?
  • What is Average Wholesale Price for BRAVNETSA?
Summary for BRAVNETSA
US Patents:0
Applicants:1
NDAs:1
DailyMed Link:BRAVNETSA at DailyMed

US Patents and Regulatory Information for BRAVNETSA

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Lantheus Medical BRAVNETSA lutetium lu-177 dotatate SOLUTION;INTRAVENOUS 217060-001 Sep 21, 2026 AP RX No No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.